From the Department of Nuclear Medicine.
Clin Nucl Med. 2022 Feb 1;47(2):e182-e183. doi: 10.1097/RLU.0000000000003838.
We present the case of a 64-year-old man with prostate adenocarcinoma, Gleason score 7, after radical prostatectomy and adjuvant radiotherapy in 2015. Because of high risk and perineural invasion, hormonotherapy was indicated. PSA levels began to rise, and at PSA level of 0.9 ng/mL, he was referred for 68Ga-PSMAPET/CT. It showed focal uptake in the right femur and diffuse tracer accumulation in bone marrow. The patient was previously diagnosed with macrocytic anemia. He underwent bone marrow biopsy. Based on clinical, laboratory, and histopathology results, myelodysplastic fibrosis was diagnosed. Diffuse uptake of 68Ga-PSMA was the sign of the bone marrow stimulation.
我们报告一例 64 岁男性前列腺腺癌病例，Gleason 评分 7，2015 年行根治性前列腺切除术和辅助放疗。由于存在高危因素和神经周围侵犯，给予了激素治疗。PSA 水平开始上升，当 PSA 水平为 0.9ng/mL 时，患者接受了 68Ga-PSMAPET/CT 检查。结果显示右侧股骨局灶性摄取和骨髓弥漫性示踪剂积聚。患者既往诊断为巨幼细胞性贫血。他接受了骨髓活检。根据临床、实验室和组织病理学结果，诊断为骨髓纤维化伴原始细胞增多。68Ga-PSMA 的弥漫性摄取是骨髓刺激的标志。
